Altimmune (ALT) Stock Forecast & Price Target

Compare

3,533 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALT Analyst Ratings

Strong Buy

3 Buy

1 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Altimmune

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALT Stock 12 Month Forecast

Average Price Target

$13.00

▲(226.63% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is $13.00 with a high forecast of $14.00 and a low forecast of $12.00. The average price target represents a 226.63% change from the last price of $3.98.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","15":"$15","5.25":"$5.25","8.5":"$8.5","11.75":"$11.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.25,8.5,11.75,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.93,5.627692307692308,6.325384615384615,7.023076923076923,7.72076923076923,8.418461538461539,9.116153846153846,9.813846153846153,10.51153846153846,11.20923076923077,11.906923076923077,12.604615384615386,13.302307692307693,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.93,5.55076923076923,6.171538461538461,6.792307692307692,7.413076923076923,8.033846153846152,8.654615384615385,9.275384615384615,9.896153846153846,10.516923076923076,11.137692307692307,11.758461538461539,12.37923076923077,{"y":13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.93,5.473846153846154,6.0176923076923075,6.561538461538461,7.105384615384615,7.649230769230769,8.193076923076923,8.736923076923077,9.28076923076923,9.824615384615385,10.368461538461538,10.912307692307692,11.456153846153846,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$13.00

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$12

Buy

201.51%

Upside

Reiterated

12/19/25

Pemvidutide’s Strong Phase 2b Data and De-Risked Phase 3 Path in MASH Support Altimmune Buy Rating and $12 Target

Annabel Samimy

Stifel Nicolaus

Buy

―

Reiterated

12/19/25

Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)

Andy Hsieh

William Blair

Hold

―

Reiterated

12/19/25

Balanced Risk-Reward for Altimmune’s Pemvidutide in a Crowded MASH Landscape Supports Hold Rating

Jonathan Wolleben

Citizens JMP

$15→$14

Buy

251.76%

Upside

Reiterated

11/07/25

Altimmune price target lowered to $14 from $15 at Citizens JMPAltimmune price target lowered to $14 from $15 at Citizens JMP

Michael DiFiore

Evercore ISI

$25

Buy

528.14%

Upside

Initiated

08/22/25

Evercore ISI Keeps Their Buy Rating on Altimmune (ALT)

Eliana Merle

UBS

$26→$24

Buy

503.02%

Upside

Reiterated

08/13/25

UBS Sticks to Their Buy Rating for Altimmune (ALT)

Mayank Mamtani

B. Riley Securities

$20→$18

Buy

352.26%

Upside

Reiterated

08/13/25

B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)

Corinne Johnson

Goldman Sachs

Sell

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Yasmeen Rahimi

Piper Sandler

$25

Buy

528.14%

Upside

Reiterated

06/27/25

Optimistic Outlook for Altimmune's Pemvidutide Despite Phase 2b Setback

Roger Song

Jefferies

$28

Buy

603.52%

Upside

Reiterated

06/26/25

Altimmune's Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$12

Buy

201.51%

Upside

Reiterated

12/19/25

Pemvidutide’s Strong Phase 2b Data and De-Risked Phase 3 Path in MASH Support Altimmune Buy Rating and $12 Target

Annabel Samimy

Stifel Nicolaus

Buy

―

Reiterated

12/19/25

Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)

Andy Hsieh

William Blair

Hold

―

Reiterated

12/19/25

Balanced Risk-Reward for Altimmune’s Pemvidutide in a Crowded MASH Landscape Supports Hold Rating

Jonathan Wolleben

Citizens JMP

$15→$14

Buy

251.76%

Upside

Reiterated

11/07/25

Altimmune price target lowered to $14 from $15 at Citizens JMPAltimmune price target lowered to $14 from $15 at Citizens JMP

Michael DiFiore

Evercore ISI

$25

Buy

528.14%

Upside

Initiated

08/22/25

Evercore ISI Keeps Their Buy Rating on Altimmune (ALT)

Eliana Merle

UBS

$26→$24

Buy

503.02%

Upside

Reiterated

08/13/25

UBS Sticks to Their Buy Rating for Altimmune (ALT)

Mayank Mamtani

B. Riley Securities

$20→$18

Buy

352.26%

Upside

Reiterated

08/13/25

B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)

Corinne Johnson

Goldman Sachs

Sell

―

Reiterated

07/18/25

We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.

Yasmeen Rahimi

Piper Sandler

$25

Buy

528.14%

Upside

Reiterated

06/27/25

Optimistic Outlook for Altimmune's Pemvidutide Despite Phase 2b Setback

Roger Song

Jefferies

$28

Buy

603.52%

Upside

Reiterated

06/26/25

Altimmune's Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Altimmune

1 Month

xxx

Success Rate

16/36 ratings generated profit

Average Return

+16.83%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 44.44% of your transactions generating a profit, with an average return of +16.83% per trade.

3 Months

xxx

Success Rate

16/36 ratings generated profit

Average Return

+25.24%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +25.24% per trade.

1 Year

Mayank MamtaniB. Riley Securities

Success Rate

16/36 ratings generated profit

Average Return

+5.49%

reiterated a buy rating 5 months ago

Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +5.49% per trade.

2 Years

xxx

Success Rate

14/35 ratings generated profit

Average Return

-9.28%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -9.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALT has received 8 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. ALT average Analyst price target in the past 3 months is 13.00.

Each month's total comprises the sum of three months' worth of ratings.

ALT Financial Forecast

ALT Earnings Forecast

Next quarter’s earnings estimate for ALT is -$0.24 with a range of -$0.30 to -$0.20. The previous quarter’s EPS was -$0.21. ALT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ALT has Performed in-line its overall industry.

ALT Sales Forecast

Next quarter’s sales forecast for ALT is $1.00K with a range of $0.00 to $5.00K. The previous quarter’s sales results were $5.00K. ALT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ALT has Performed in-line its overall industry.

ALT Stock Forecast FAQ

What is ALT’s average 12-month price target, according to analysts?

Based on analyst ratings, Altimmune Inc’s 12-month average price target is 13.00.

What is ALT’s upside potential, based on the analysts’ average price target?

Altimmune Inc has 226.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALT a Buy, Sell or Hold?

Altimmune Inc has a consensus rating of Strong Buy which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

What is Altimmune Inc’s price target?

The average price target for Altimmune Inc is 13.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $12.00. The average price target represents 226.63% Increase from the current price of $3.98.

What do analysts say about Altimmune Inc?

Altimmune Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of ALT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Altimmune (ALT) Stock Forecast & Price Target

ALT Analyst Ratings

ALT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Altimmune

ALT Analyst Recommendation Trends

ALT Financial Forecast

ALT Earnings Forecast

ALT Sales Forecast

ALT Stock Forecast FAQ

Detailed List of Analyst Forecasts